A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Interventional Study of JNJ-61178104 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
At a glance
- Drugs JNJ 61178104 (Primary) ; JNJ 61178104 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 20 Jan 2017 Status changed from recruiting to completed.
- 20 May 2016 According to a Genmab media release, first participants has been dosed in this trial.
- 20 May 2016 Status changed from not yet recruiting to recruiting, according to a Genmab media release,